Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of once-weekly redalsomatropin alfa versus daily somatropin in Japanese children with growth hormone deficiency
jRCT2031240282Phase 3Active, not recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in growth hormone deficiency (GHD) comparing JR-142 once weekly with GROWJECT daily (2 arms). Primary endpoint: Change in height SDS for chronological age from first administration at Week 53. Started Sep 2024; status: active, not recruiting.
02
Drugs
redalsomatropin alfasomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCT2031240282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240282.